Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation

Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation Emilia Solinas, Eugenia Nikolsky, Alexandra J. Lansky, Ajay J. Kirtane, Marie-Claude Morice, Jeffrey J. Popma, Joachim Schofer, Erick Schampaert, Tereza Pucelikova, Jiro Aoki, Martin Fahy, George D. Dangas, Jeffrey W. Moses, Donald E. Cutlip, Martin B. Leon, Roxana Mehran In this analysis of pooled data from the RAVEL (Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization), SIRIUS (SIRolImUS-coated Bx velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions), E-SIRIUS (Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries), and C-SIRIUS (Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries) trials, sirolimus-eluting stent (SES) versus bare metal-stent (BMS) implantation was associated with significant reductions in rates of in-segment binary restenosis both in women (6.3% vs. 43.8%) and in men (6.4% vs. 35.6%), as well as reductions in adverse clinical outcomes in both genders. By multivariable analysis, female gender was not an independent predictor of restenosis and clinical outcomes in SES- or BMS-treated patients.